TCIM
VYNE icon

TIAA CREF Investment Management’s VYNE Therapeutics VYNE Stock Holding History

TIAA CREF Investment Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$179K Buy
+317
New +$152K ﹤0.01% 2903
2018
Q4 		– Sell
-259
Closed -$184K – 3030
2018
Q3 		$184K Buy
+259
New +$160K ﹤0.01% 2998
2018
Q2 		– Sell
-165
Closed -$448K – 3120
2018
Q1 		$448K Buy
+165
New +$401K ﹤0.01% 2787

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

TIAA CREF Investment Management's VYNE Position: Q1 2019 in Review

TIAA CREF Investment Management opened a new position in VYNE Therapeutics (VYNE) in Q1 2019: 317 shares worth $179K. The stake represents ﹤0.01% of the portfolio and ranks #2903 among its holdings. This is a return to the name: TIAA CREF Investment Management previously reported a position in VYNE as recently as Q3 2018.

TIAA CREF Investment Management first reported a position in VYNE in Q1 2018 and has held it in 3 quarters since. The position peaked at $448K in Q1 2018. 59 funds tracked by Wall St. Rank hold VYNE as of Q1 2019.

  • TIAA CREF Investment Management held 317 shares of VYNE Therapeutics worth $179K as of Q1 2019.
  • VYNE Therapeutics was a new TIAA CREF Investment Management position in Q1 2019.
  • VYNE Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2903 holding.
  • TIAA CREF Investment Management first reported a position in VYNE Therapeutics in Q1 2018 and has held it in 3 quarters since.
  • TIAA CREF Investment Management's VYNE Therapeutics position peaked at $448K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.